Drug intelligence / Profile preview

KBD111

Development stage: Preclinical
Lead developer: Baiyu Pharmaceutical
Modality: Small Molecules
Administration: Intrastromal

Overview

KBD111 is a preclinical, investigational drug that functions as a PARP1 inhibitor. It was initially developed by Chengdu Baiyu Pharmaceutical. PARP1 inhibitors act by blocking the enzyme poly(ADP-ribose) polymerase 1, which is involved in DNA repair processes. This mechanism can sensitize cancer cells to DNA damage and is frequently used as a strategy in oncology, particularly for tumors with deficiencies in DNA repair pathways. KBD111's primary indication or target disease has not been definitively specified in public sources, and its current development is preclinical.

Other names: KBD-111KBD111KBD 111

Targets

PARP1 (Poly (adp-ribose) polymerase 1)

Beyond the preview

Go deeper on KBD111.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KBD111.

Explore the full profile